Human cytomegalovirus UL54 and UL97 mutations for detection of ganciclovir resistance in congenital infection. (October 2017)

• Record Type: Journal Article
• Authors: Javid, Naeme; Talkhabifard, Majid; Tabarraei, Alijan; Moradi, Abdolvahab
• Is Part Of: Future virology. Volume 12:Number 10(2017)
• Page Start: 561
• Page End: 567
• Publication Date: 2017-10
• Subjects: congenital -- ganciclovir -- human cytomegalovirus -- IRAN -- mutation -- polymerase chain reaction -- polymorphism -- resistance -- UL54 -- UL97; Virology -- Periodicals; Virus diseases -- Treatment -- Periodicals; 616.9101
• DOI: 10.2217/fvl-2017-0018
• Languages: English
• ISSNs: 1746-0794

Abstract

Aim: Ganciclovir (GCV) is used as an antiviral drug for the treatment of human cytomegalovirus infection. The aim of this study was to demonstrate GCV-resistant human cytomegalovirus in congenitally infected neonates.Patients & methods: DNA of CMV positive newborn samples was extracted and UL97 and UL54 genes were amplified by PCR and real-time PCR. Sequencing of UL97 and UL54 genes were performed and analyzed.Results: UL97 GCV resistance mutation C603W was detected in one newborn. D605E was the most common polymorphism in UL97 observed in 7/13 (53.8%) of samples. N685S, A688V, A885T and N898D were four known common UL54 polymorphisms.Conclusion: The rate of GCV resistance in congenital CMV is low. Common polymorphisms in UL97 and UL54 genes are also reported as new mutations.